Compromised sexual function is often a side effect for patients following radical surgical procedures for bladder or prostate cancer.
Methods
The authors review the classification and physiology of sexual function and dysfunction. Moreover, they explain the possible pathophysiology directly resulting from surgery, and they discuss several approaches available to address these problems.
Results
Options for male sexual dysfunction, primarily erectile dysfunction resulting from radical prostatectomy or surgery for bladder cancer, range from patient education to penile prosthesis implantation. Female sexual dysfunction caused by surgical intervention for bladder cancer includes problems with libido, arousal, orgasm, and dyspareunia. Treatment options for women can include sex therapy, hormonal therapy, and preventive strategies. However, no consensus has been established on the most effective agents and time points to treat male or female sexual dysfunction following radical cystectomies or prostatectomies. The chronic intermittent treatment of erectile dysfunction following radical prostatectomy has been commonly referred to as penile rehabilitation.
Conclusions
Additional research is needed to obtain further data concerning sexual dysfunction in both men and women following radical pelvic surgeries. Modification of surgical techniques, the use of various treatment modalities for sexual dysfunction, and the development of new agents will help to successfully minimize or prevent damage and restore normal sexual function after local surgical therapy for prostate or bladder cancer in the future.
References
1.
BassonR., BermanJ., BurnettA.Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol.2000; 163: 888–893.
2.
World Health Organization: ICD-10: International Statistical Classification of Diseases and Related Health Problems.World Health Organization: Geneva; 1992.
3.
NIH Consensus Conference.Impotence. NIH Consensus Development Panel on Impotence. JAMA.1993; 270: 83–90.
4.
McKinlayJ.B.The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res.2000; 12(Suppl 4): S6–S11.
5.
LaumannE.O., PaikA., RosenR.C.Sexual dysfunction in the United States: prevalence and predictors. JAMA.1999; 281: 537–544. Erratum in: JAMA. 1999; 281: 1174.
6.
DennersteinL., RandolphJ., TaffeJ.Hormones, mood, sexuality, and the menopausal transition. Fertil Steril.2002; 77(Suppl 4): S42–48.
7.
JemalA., SiegelR., WardE.Cancer statistics, 2006. CA Cancer J Clin.2006; 56: 106–130.
8.
NelsonW.G., De MarzoA.M., IsaacsW.B.Prostate cancer. N Engl J Med.2003; 349: 366–381.
9.
LotanY., RoehrbornC.G.Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology.2003; 61: 109–118; discussion 118.
10.
KamatA.M., LammD.L.Chemoprevention of urological cancer. J Urol.1999; 161: 1748–1760.
11.
CarrionR., SeigneJ.Surgical management of bladder carcinoma. Cancer Control.2002; 9: 284–292.
12.
LueT.F., TakamuraT., SchmidtR.A.Hemodynamics of erection in the monkey. J Urol.1983; 130: 1237–1241.
13.
RajferJ., AronsonW.J., BushP.A.Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, non-cholinergic neurotransmission. N Engl J Med.1992; 326: 90–94.
14.
LueT.F.Erectile dysfunction. N Engl J Med.2000; 342: 1802–1813.
15.
AnderssonK.E., WagnerG.Physiology of penile erection. Physiol Rev.1995; 75: 191–236.
16.
KwanM., GreenleafW.J., MannJ.The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab.1983; 57: 557–562.
17.
BancroftJ., WuF.C.Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav.1983; 12: 59–66.
18.
StiefC.G., UckertS., BeckerA.J.The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol.1998; 159: 1390–1393.
19.
De LucaV., PescatoriE.S., TaherB.Damage to the erectile function following radical pelvic surgery: prevalence of veno-occlusive dysfunction. Eur Urol.1996; 29: 36–40.
20.
UserH.M., HairstonJ.H., ZelnerD.J.Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol.2003; 169: 1175–1179.
21.
MastersW.H., JohnsonV.E.The sexual response cycle of the human female. III. The clitoris: anatomic and clinical consideration. West J Surg Obstet Gynecol.1962; 70: 248–257.
22.
MastersW.H., JohnsonV.E.The sexual response of the human male. I. Gross anatomic considerations. West J Surg Obstet Gynecol.1963; 71: 85–95.
23.
BassonR.Female sexual response: the role of drugs in the management of sexual dysfunction. Obstet Gynecol.2001; 98: 350–353.
24.
MahK., BinikY.M.The nature of human orgasm: a critical review of major trends. Clin Psychol Rev.2001; 21: 823–856.
25.
LaanE., EveraerdW.Physiological measures of vaginal vasocongestion. Int J Impot Res.1998; 10(Suppl 2): S107–110; discussion S124-125.
26.
WalshP.C., PartinA.W., EpsteinJ.I.Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol.1994; 152(5 Pt 2): 1831–1836.
27.
CatalonaW.J., CarvalhalG.F., MagerD.E.Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol.1999; 162: 433–438.
28.
RabbaniF., StapletonA.M., KattanM.W.Factors predicting recovery of erections after radical prostatectomy. J Urol.2000; 164: 1929–1934.
29.
WalshP.C.Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol.2000; 164: 242.
FowlerF.J.Jr, BarryM.J., Lu-YaoG.Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology.1993; 42: 622–629.
32.
SiegelT., MoulJ.W., SpevakM., AlvordW.G., CostabileR.A.The development of erectile dysfunction in men treated for prostate cancer. J Urol.2001; 165(2): 430–435.
33.
TalcottJ.A., RiekerP., ClarkJ.A.Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol.1998; 16: 275–283.
34.
QuinlanD.M., EpsteinJ.I., CarterB.S.Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol.1991; 145: 998–1002.
35.
LeandriP., RossignolG., GautierJ.R.Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol.1992; 147(3 Pt 2): 883–887.
36.
PodlasekC.A., GonzalezC.M., ZelnerD.J.Analysis of NOS iso-form changes in a post radical prostatectomy model of erectile dysfunction. Int J Impot Res.2001; 13(Suppl 5): S1–15.
37.
BahnsonR.R., CatalonaW.J.Papaverine testing of impotent patients following nerve-sparing radical prostatectomy. J Urol.1988; 139: 773–774.
DroupyS., HesselA., BenoitG.Assessment of the functional role of accessory pudendal arteries in erection by transrectal color Doppler ultrasound. J Urol.1999; 162: 1987–1991.
40.
FraimanM.C., LeporH., McCulloughA.R.Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical retropubic prostatectomy. Mol Urol.1999; 3: 109–115.
41.
IaconoF., GiannellaR., SommaP.Histological alterations in cavernous tissue after radical prostatectomy. J Urol.2005; 173: 1673–1676.
42.
NehraA., GoldsteinI., PabbyA.Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol.1996; 156: 1320–1329.
43.
KleinL.T., MillerM.I., ButtyanR.Apoptosis in the rat penis after penile denervation. J Urol.1997; 158: 626–630.
44.
StenzlA., ColleselliK., PoiselS.Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women. J Urol.1995; 154: 2044–2049.
45.
SteinJ.P., EsrigD., FreemanJ.A.Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology.1998; 51: 951–955.
46.
SchoenbergM., HortopanS., SchlossbergL.Anatomical anterior exenteration with urethral and vaginal preservation: illustrated surgical method. J Urol.1999; 161: 569–572.
47.
ZippeC.D., RainaR., ShahA.D.Female sexual dysfunction after radical cystectomy: a new outcome measure. Urology.2004; 63: 1153–1157.
Weijmar SchultzW.C., Van De WielH.B., HahnD.E.Psychosexual functioning after treatment for gynecological cancer: an integrative model, review of determinant factors and clinical guidelines. Int J Gynecol Cancer.1992; 2: 281–290.
50.
AlthofS.E., TurnerL.A., LevineS.B.Through the eyes of women: the sexual and psychological responses of women to their partner's treatment with self-injection or external vacuum therapy. J Urol.1992; 147: 1024–1027.
51.
RosenR.C., TaylorJ.F., LeiblumS.R.Prevalence of sexual dysfunction in women: results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther.1993; 19: 171–188.
52.
BjerreB.D., JohansenC., StevenK.A questionnaire study of sexological problems following urinary diversion in the female patient. Scand J Urol Nephrol.1997; 31: 155–160.
53.
GoldsteinI., LueT.F., Padma-NathanH.Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med.1998; 338: 1397–1404. Erratum in: N Engl J Med. 1998; 339: 59.
54.
KaplanS.A., ReisR.B., KohnI.J.Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology.1999; 53: 481–486.
55.
CarusoS., IntelisanoG., LupoL.Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, crossover, placebo-controlled study. BJOG.2001; 108: 623–628.
ColomboR., BertiniR., SaloniaA.Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer. J Urol.2004; 171: 1819–1822.
58.
BurdayD., WeberT., ThurmanS.Prostate-Sparing Radical Cystectomy: Erectile Function and Continence. J Urol.2005; 173: 93.
59.
SaidiA., NahonO., DanielL.Prostate-sparing cystectomy: long-term functional and oncological results in a series of 25 cases. Prog Urol.2004; 14: 172–177.
60.
SebeP., TraxerO., CussenotO.Cystectomy with preservation of the prostate in the treatment of bladder tumours: anatomical basis, surgical techniques, indications and results. Prog Urol.2003; 13: 1279–1285.
61.
ZhouF.J., QinZ.K., HanH.Radical cystectomy with sparing partial prostate for invasive bladder cancer. Ai Zheng.2003; 22: 1066–1069.
62.
MeinhardtW., HorenblasS.Sexuality preserving cystectomy and neobladder (SPCN): functional results of a neobladder anastomosed to the prostate. Eur Urol.2003; 43: 646–650.
63.
VallancienG., Abou El FettouhH., CathelineauX.Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol.2002; 168: 2413–2417.
64.
CarsonC., GiulianoF., GoldsteinI.The ‘effectiveness’ scale — therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res.2004; 16: 207–213.
65.
ZippeC.D., JhaveriF.M., KleinE.A.Role of Viagra after radical prostatectomy. Urology.2000; 55: 241–245.
66.
ZagajaG.P., MhoonD.A., AikensJ.E.Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology.2000; 56: 631–634.
BrockG., NehraA., LipshultzL.I.Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol.2003; 170(4 Pt 1): 1278–1283.
69.
MontorsiF., NathanH.P., McCulloughA.Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol.2004; 172: 1036–1041.
ValenteE.G., VernetD., FerriniM.G.L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide.2003; 9: 229–244.
72.
CostabileR.A., SpevakM., FishmanI.J.Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol.1998; 160: 1325–1328.
73.
RainaR., AgarwalA., AusmundsonS.Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res.2005; 17: 86–90.
74.
MontorsiF., GuazzoniG., StrambiL.F.Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol.1997; 158: 1408–1410.
75.
MarmarJ.L., DeBenedictisT.J., PraissD.E.The use of a vacuum constrictor device to augment a partial erection following an intracavernous injection. J Urol.1988; 140: 975–979.
76.
BanielJ., IsrailovS., SegenreichE.Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int.2001; 88: 58–62.
77.
GoldsteinI., BerteroE.B., KaufmanJ.M.Early experience with the first pre-connected 3-piece inflatable penile prosthesis: the Mentor Alpha-1. J Urol.1993; 150: 1814–1818.
78.
DavisS.R., McCloudP., StraussB.J.Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas.1995; 21: 227–236.
79.
KaiserF.E.Sexuality in the elderly. Urol Clin North Am.1996; 23: 99–109.
80.
ShifrenJ.L., BraunsteinG.D., SimonJ.A.Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med.2000; 343: 682–688.
81.
LundbergP.O., HulterB.Sexual dysfunction in patients with hypothalamo-pituitary disorders. Exp Clin Endocrinol.1991; 98: 81–88.
82.
DavisS.R., BurgerH.G.Clinical review 82: androgens and the postmenopausal woman. J Clin Endocrinol Metab.1996; 81: 2759–2763.
83.
DavisS.R.The role of androgens and the menopause in the female sexual response. Int J Impot Res.1998; 10(Suppl 2): S82–83; discussion S98-101.
84.
BassonR., McInnesR., SmithM.D.Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med.2002; 11: 367–377.
85.
Padma-NathanH., BrownC., FendlJ.Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial. J Sex Marital Ther.2003; 29: 329–434.
86.
KatzS., MoralesA.J.Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause. Semin Reprod Endocrinol.1998; 16: 161–170.
87.
CroweM., JonesM.Sex therapy: the successes, the failures, the future. Br J Hosp Med.1992; 48: 474–479, 482.
88.
Cartwright-AlcareseF.Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy. Oncol Nurs Forum.1995; 22: 1227–1232.
89.
GonteroP., KirbyR.Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP). Prostate Cancer Prostatic Dis.2004; 7: 223–226.
90.
ManciniM., BartoliniM., MaggiM.Duplex ultrasound evaluation of cavernosal peak systolic velocity and waveform acceleration in the penile flaccid state: clinical significance in the assessment of the arterial supply in patients with erectile dysfunction. Int J Androl.2000; 23: 199–204.
91.
ManciniM., RainaR., AgarwalA.Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study. Int J Impot Res.2004; 16: 8–12.
